Table 2 Adjusted mixed-effects model results investigating the relationship between PD medication and depression symptom dimension longitudinally (drug × time) and across all time points (drug)

From: Dissociable effects of dopaminergic medications on depression symptom dimensions in Parkinson disease

Medication

 

‘Motivation’ factor

‘Depression’ factor

Dopamine agonists

drug

0.15 (−0.06 to 0.36)

−0.03 (−0.16 to 0.11)

drug × time

−0.06 (−0.13 to −0.01), P = 0.039*

0.01 (−0.02 to 0.05)

Levodopa

drug

−0.15 (−0.35 to 0.05)

0.00 (−0.12 to 0.13)

drug × time

0.04 (−0.02 to 0.09)

0.01 (−0.03 to 0.04)

MAO-B inhibitors

drug

−0.08 (−0.29 to 0.12)

−0.14 (−0.27 to −0.02), P = 0.026*

drug × time

−0.01 (−0.07 to 0.04)

0.03 (−0.01 to 0.07)

COMT inhibitors

drug

0.04 (−0.94 to 1.00)

0.48 (−0.14 to 1.1)

drug × time

−0.01 (−0.24 to 0.22)

−0.08 (−0.23 to 0.07)

Amantadine

drug

0.11 (−0.18 to 0.39)

−0.05 (−0.23 to 0.13)

drug × time

−0.06 (−0.15 to 0.01)

0.01 (−0.04 to 0.06)

  1. *P < 0.05, statistically significant results in bold.
Back to article page